B O O K - American College of Rheumatology

ACR Poster Session A
51. Association of Patient Cost-Cutting Behaviors with Clinical
Outcomes, Health Status, and Lost Work Productivity in
Individuals with Rheumatoid Arthritis. Susan C. Bolge 1 , Ahmad
B. Naim 2 , Chureen Carter 2 , Marco DiBonaventura 3 and Mike
Ingham 2 , 1 Centocor Ortho Biotech Services, LLC, Horsham, PA,
2
Centocor Ortho Biotech Services, LLC, 3 KantarHealth.
52. Baseline Factors Related to Response to Conventional DMARD
Treatments. Kimberly L. Sterling 1 , Gebra Cuyun Carter 1 , Susan
Messing 6 , George Reed 5 , Rui Chen 6 , Kimberly Kaukeinen 6 , Xin
Tu 6 , David R. Nelson 2 , Khaled Sarsour 3 , Ronald A. Cantrell 3 ,
Carlos I. Alatorre 3 and Jeffrey Greenberg 4 , 1 Eli Lilly and Co,
Indianapolis, IN, 2 Eli Lilly and Co, 3 Eli Lilly and Co, Indianapolis,
IN, 4 New York University School of Medicine, New York, NY,
5
University of Massachusetts, Amherst, MA, 6 University of
Rochester, Rochester, NY.
53. Cerebrovascular and Venous Thromboembolic Events Predict
Mortality in Rheumatoid Arthritis. A. Kirstin Bacani 2 , Sherine E.
Gabriel 2 , Cynthia S. Crowson 1 and Eric L. Matteson 2 , 1 Rochester,
MN, 2 Mayo Clinic, Rochester, MN.
54. Changes in Corticosteroid Use after DMARD Initiation in
Patients with Rheumatoid Arthritis. Vivian K. Kawai 5 , Carlos
Grijalva 6 , Patrick Arbogast 6 , Jeffrey R. Curtis 4 , Daniel Hal
Solomon 1 , Elizabeth Delzell 3 , Rita Ouellet-Hellstrom 2 , Ed
Mitchel 6 , C. Michael Stein 5 and Marie R. Griffin 6 , 1 Brigham and
Womens Hospital, Boston, MA, 2 FDA, 3 University of Alabama,
4
University of Alabama - Brimingham, Birmingham, AL,
5
Vanderbilt University, Nashville, TN, 6 Vanderbilt University.
55. Changes in EQ-5D and SF-6D during Rituximab Treatment
– Results from the CERERRA Collaboration. Elisabeth Lie 5 ,
Katerina Chatzidionysiou7, Evgeny Nasonov9, Galina Lukina9,
Cem Gebay 12 , Karel Pavelka 2 , Dan Nordström 6 , Matija Tomsic 13 ,
Merete L. Hetland 3 , Ulrik Tarp 1 , Piet L. C. M. van Riel 1 0, Juan J.
Gomez-Reino 11 , Ronald Van Vollenhoven8 and Tore K. Kvien 5 ,
1
Aarhus University Hospital, Aarhus, Denmark, 2 Charles
University, Prague, Czech Republic, 3 Copenhagen University
Hospital at Glostrup/DANBIO Registry, Copenhagen, Denmark,
4
Diakonhjemmet Hospital, Oslo, Norway, 5 Diakonhjemmet
Hospital, Oslo, Norway, 6 Helsinki University Central Hospital,
Helsinki, Finland, 7 Karolinska University Hospital, Stockholm,
Sweden, 8 Karolinska University Hospital, Stockholm, Sweden,
9
Moscow Institute of Rheumatology, Moscow, Russian
Federation, 10 Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands, 11 University Hospital of Santiago,
Santiago, Spain, 12 University Hospitals of Geneva/SCQM
Registry, Geneva, Switzerland, 13 University Medical Center of
Ljubljana, Ljubljana, Slovenia.
56. Comparison of the Efficacy of Tocilizumab and TNFα-Inhibitors
on the DAS28 in “Real Life” Conditions in Rheumatoid Arthritis
(RA) Patients after DMARD Failure. Jörg Kaufmann 2 , Eugen
Feist 1 , Hagen Schmidt 3 , Anne-Eve Roske 4 and Adrian Kielhorn 4 ,
1
Campus Charité Mitte, Med. Klinik Abt. Rheumatologie u.
Klin. Immunologie, Berlin, Germany, 2 Praxis für Innere Medizin
und Rheumatologie, Ludwigsfelde, Germany, 3 Praxis für Innere
Medizin und Rheumatologie, Berlin, Germany, 4 Roche Pharma
AG, Grenzach-Whylen, Germany.
57. Demyelinating Events in Seniors with Rheumatoid Arthritis
(RA): A Population-Based Study. Jessica Widdifield 7 , Sasha R.
Bernatsky 2 , J. Michael Paterson 1 , Nadia Gunraj 1 , Janet E. Pope 5 ,
J. Carter Thorne 4 , Alfred A. Cividino 3 and Claire Bombardier 6 ,
1
Institute for Clinical Evaluative Science, 2 McGill UHC/RVH,
Montreal, QC, Canada, 3 McMaster University, Hamilton, ON,
Canada, 4 Southlake Regional Health Care, Newmarket, ON,
Canada, 5 St Joseph Health Care London, London, ON, Canada,
6
University of Toronto, Toronto, ON, Canada, 7 University of
Toronto.
58. Descriptive Epidemiology of Adult Rheumatoid Arthritis in
an Insurance Claims Database. Martin M. Crane 1 , Maneesh
Juneja 3 , Fayaz A. Aziz 3 , Regina H. Kurrasch 2 , Myron E. Chu 2 ,
Emilia Quattrocchi 3 , Stephanie Manson 4 and David J. Chang 2 ,
1
GlaxoSmithKline R&D, Research Triangle, NC, 2 GlaxoSmithKline
R&D, King of Prussia, PA, 3 GlaxoSmithKline R&D, 4 United
Biosource.
59. Different Factors Are Important for RA Patients and
Rheumatologists Regarding DMARD Escalation. Laura van
Hulst 2 , Wietske Kievit 1 , Piet van Riel 2 and Liana Fraenkel 3 ,
1
Radboud University Nijmegen Medical Centre, Department of
Rheumatology, Nijmegen, The Netherlands, 2 Radboud University
Nijmegen Medical Centre, Department of Rheumatology, 3 Yale
University School of Medicine, Department of Medicine, VA
Connecticut Healthcare System, Section of Rheumatology.
60. DMARD Use for Rheumatoid Arthritis as Reported in the
National Ambulatory Medical Care Survey, 1996-2007. Daniel
Hal Solomon 4 , John Ayanian 3 , M. Alan Brookhart 6 , Sebastian
Schneeweiss 2 , Tamara Shaykevich 2 , Edward H. Yelin 5 and Jeffrey
N. Katz 1 , 1 Brigham & Womens Hosp, Boston, MA, 2 Brigham and
Women’s Hospital, 3 Brigham and Women’s Hospital, Harvard
Medical School, 4 Brigham and Womens Hospital, Boston, MA,
5
University of California, San Francisco, CA, 6 University of North
Caroline.
61. Early Life Socioeconomic Factors and Rheumatoid Arthritis
(RA) in Adulthood. Christine G. Parks 2 , Aimee A. D’Aloisio 1 , Lisa
A. DeRoo 1 , Huiber Kirstin 3 and Dale P. Sandler, 1 National Institute
of Environmental Health Science, Research Triangle Park, NC,
2
National Institute of Environmental Health Science, Research
Triangle Park, NC, 3 UNC, School of Public Health, Chapel Hil NC.
62. Effect of Disease-Modifying Anti-Rheumatic Drug (DMARD)
Exposure on Head and Neck Cancer in a National Cohort of
Veterans with Rheumatoid Arthritis. Christopher R. Phillips 2 ,
Angelique L. Zeringue 3 , Jay R. McDonald 1 , Seth A. Eisen 3 , Liron
Caplan 4 and Prabha Ranganathan 5 , 1 Division of Infectious
Disease, St. Louis Veterans Affairs Medical Center, 2 Division
of Rheumatology, Washington University School of Medicine,
Paducah, KY, 3 St. Louis Veterans Affairs Medical Center, 4 Univ of
CO-Denver Med Sc, Aurora, CO, 5 Washington University School
of Medicine, St. Louis, MO.
63. Elaboration and Validation of a Questionnaire To Assess the
Impact of Rheumatoid Arthritis (RA) on Sexuality, with Patient
Involvement: QUALISEX. Laure Gossec 2 , Catherine Solano 4 ,
Simon Paternotte 2 , Catherine Beauvais 3 , Christelle Sordet 6 ,
Philippe Gaudin 1 and Aleth Perdriger 5 , 1 Grenoble University
Hospital, France, 2 Paris Cochin University Hospital, France,
3
Paris Saint Antoine University Hospital, France, 4 Paris, France,
5
Rennes University Hospital, France, 6 Strasbourg University
Hospital, France.
64. Geographical Variation of Rheumatoid Arthritis in Stockholm
County, Sweden. Henrik Källberg 4 , Veronica M. Vieira 2 , Jamie E.
Hart 1 , Karen H. Costenbader 3 , Marie Holmqvist 5 , Lars Klareskog 6 ,
Lars Alfredsson 5 and Elizabeth W. Karlson 3 , 1 Channing
Laboratory, Department of Medicine, Brigham and Women’s
Hospital and Harvard Medical School, Boston Massachusetts,
Department of Epidemiology, Harvard School of Public Health,
Boston Massachusetts, 2 Department of Environmental Health,
Boston University School of Public Health, Boston, MA,
3
Division of Rheumatology, Immunology and Allergy, Brigham
and Women’s Hospital and Harvard Medical School, Boston
Massachusetts, 4 Institute of Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden, 5 Institute of Environmental
Medicine, Karolinska Institutet, Stockholm, Sweden,
6
Rheumatology Unit, Department of Medicine, Karolinska
Institutet/Karolinska Hospital, Stockholm, Sweden.
2010 Program Book 151